证券记录 · 已归档季度
NVS
Novartis AG · Healthcare · Drug Manufacturers - General
20被追踪持有人
-1Δ持有人
49.48M持有股份
$6.35B报告持仓市值
+0新建仓位
−1清仓
动量输入（同类管理人）：
持有人广度 -4.8% ·
股份流向 -7.9% ·
净新建仓位 -5.0%
· 公式
广泛减持：持股数量下降，持有人数量减少
所有持股数据：仅限已追踪的 13F 管理人，普通股持仓，报告期 Q3 2025
持股变化趋势
| 季度 | 持有人 | Δ | 股份 | 报告持仓市值 | 新增 | 清仓 |
|---|---|---|---|---|---|---|
| Q3 2026 | 3 | 0 | 239.53K | $32.26M | n/a | −2 |
| Q2 2026 | 123 | 0 | 102.12M | $16.00B | +8 | −9 |
| Q1 2026 | 126 | +1 | 113.27M | $17.29B | +8 | −7 |
| Q4 2025 | 124 | +1 | 102.45M | $14.13B | +1 | n/a |
| Q3 2025 | 20 | -1 | 49.48M | $6.35B | n/a | −1 |
| Q2 2025 | 18 | 0 | 41.97M | $5.08B | +2 | −2 |
| Q1 2025 | 16 | +1 | 41.02M | $4.58B | +1 | n/a |
| Q4 2024 | 15 | +1 | 35.01M | $3.41B | +1 | n/a |
| Q3 2024 | 13 | 0 | 33.66M | $3.89B | n/a | n/a |
| Q2 2024 | 13 | n/a | 33.92M | $3.61B | n/a | n/a |
持有人 · Q3 2025
| # | 管理人 | 股份 | Δ股份 | 价值 | 其权重 | 持有 | ||
|---|---|---|---|---|---|---|---|---|
| 1 | Dodge & Cox ✦ | 10.59M | -0.6% | $1.36B | 0.7% | ▼ Trim | 6 | SEC ↗ |
| 2 | PRIMECAP Management ✦ | 9.34M | -10.2% | $1.20B | 0.9% | ▼ Trim | 6 | SEC ↗ |
| 3 | Morgan Stanley ✦ | 7.73M | n/a | $991.15M | 0.1% | n/c | 1 | SEC ↗ ×11 |
| 4 | Fisher Asset Management ✦ | 7.24M | +1.7% | $928.38M | 0.3% | ▲ Add | 6 | SEC ↗ |
| 5 | Goldman Sachs Group ✦ | 2.95M | n/a | $378.26M | 0.1% | n/c | 1 | SEC ↗ ×3 |
| 6 | BlackRock ✦ (被动) | 2.53M | +9.0% | $324.47M | 0.0% | ▲ Add | 2 | SEC ↗ ×5 |
| 7 | Renaissance Technologies ✦ | 1.88M | -18.3% | $240.81M | 0.3% | ▼ Trim | 6 | SEC ↗ |
| 8 | Fidelity (FMR) ✦ | 1.60M | +3.8% | $205.15M | 0.0% | ▲ Add | 2 | SEC ↗ ×4 |
| 9 | State Street Global Advisors ✦ (被动) | 1.50M | -6.1% | $194.60M | 0.0% | ▼ Trim | 4 | SEC ↗ |
| 10 | Wellington Management ✦ | 1.40M | -43.9% | $180.06M | 0.0% | ▼ Trim | 6 | SEC ↗ ×3 |
| 11 | Marshall Wace ✦ | 1.17M | -18.4% | $149.88M | 0.2% | ▼ Trim | 4 | SEC ↗ ×2 |
| 12 | JPMorgan Chase ✦ | 1.08M | n/a | $137.87M | 0.0% | n/c | 1 | SEC ↗ ×22 |
| 13 | Adage Capital Partners ✦ | 210.19K | +1351.5% | $26.95M | 0.0% | ▲ Add | 2 | SEC ↗ |
| 14 | AQR Capital Management ✦ | 135.96K | +85.0% | $17.44M | 0.0% | ▲ Add | 6 | SEC ↗ ×4 |
| 15 | Tweedy, Browne ✦ | 76.05K | -1.6% | $9.75M | 0.8% | ▼ Trim | 6 | SEC ↗ |
| 16 | Two Sigma Investments ✦ | 31.73K | -90.5% | $4.07M | 0.0% | ▼ Trim | 6 | SEC ↗ |
| 17 | Millennium Management ✦ | 9.97K | -98.8% | $1.28M | 0.0% | ▼ Trim | 6 | SEC ↗ |
| 18 | T. Rowe Price ✦ | 6.24K | -4.6% | $802,000 | 0.0% | ▼ Trim | 6 | SEC ↗ ×2 |
| 19 | D. E. Shaw & Co. ✦ | 4.71K | -62.6% | $603,498 | 0.0% | ▼ Trim | 6 | SEC ↗ ×2 |
| 20 | Gotham Asset Management ✦ | 1.96K | +10.8% | $250,837 | 0.0% | ▲ Add | 2 | SEC ↗ |
"持仓权重"指该仓位占该管理人13F申报股票组合市值的比例，即持仓信心指标。✦ = 精选管理人。
新增买入方
| 本季度无新增被追踪买入方。 |
已清仓
| Point72 Asset Management | $90.36M | 曾为 0.2% |
全市场背景: 涵盖所有13F申报机构（SEC结构化数据， Q1 2026): 2 持有人, 1.31M 股份, $431.09M 已申报. 这是与上方被追踪全域数据不同的较早期间，两者从不混用。
常见共同持仓
持有该证券的受追踪机构最常同时持有的其他证券：基于共同持有计数，而非基本面关联。
数据来源: 持股数据来源于已解析的13F普通股持仓（被追踪范围，变动对比集）；内部人行为来自Form 3/4/5；重大持股来自Schedule 13D/13G；所有文件均链接至SEC EDGAR原始申报。
报告期: Q3 2025 ·
方法论 ·
通过API获取此数据